539730 — Fredun Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Fredun Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,217	2,743	3,466	4,538	6,391
Cost of Revenue
Gross Profit	384	570	725	1,064	1,693
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	2,101	2,490	3,123	4,063	5,528
Operating Profit	117	253	343	475	863
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	86	175	215	275	470
Provision for Income Taxes
Net Income After Taxes	63.4	108	156	197	326
Net Income Before Extraordinary Items
Net Income	63.4	108	156	197	326
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	63.4	108	156	197	326
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	14.2	23	33.2	42.7	61.2
Dividends per Share